Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia
US5585348A · kind A · utility
115Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 13, 1993 |
| Grant date | Dec 17, 1996 |
| Priority date | — |
| Expiry date | Aug 13, 2013 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to a method of preventing hyperalgesia and other undesirable side-effects associated with the administration of growth factor, including nerve growth factor, utilizing an antagonist capable of inactivating excitatory opioid receptor-mediated functions on neurons in the nociceptive pathway. In addition, this invention relates to a composition comprising a growth factor and an antagonist capable of inactivating excitatory opioid receptor-mediated functions on neurons in the nociceptive pathway.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.